Omeros Corp (Omeros) is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s marketed product, Omidria is a phenylephrine and ketorolac injection for use during cataract surgery or replacement of intraocular lens (IOL). The company is investigating its product candidates for use in arthroscopic, ophthalmological, and other surgical procedures including thrombotic microangiopathies, mediated glomerulopathies, addictive and compulsive disorders among others. It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

Headquarters United States of America

Address 201 Elliott Avenue West, Seattle, Washington, 98119


Telephone 1 206 6765000

No of Employees 213

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange OMER (NASD)

EPS XXX

Net Income (2021) XXX 240.7% (2021 vs 2020)

Market Cap* $134.2M

Net Profit Margin (2018) XXX 0.0% (2021 vs 2020)

   

* As of and is in US$

Access premium data and analytics for Omeros Corp

70+

Pipeline Drugs

Identify which of Omeros Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Clinical Trials

Determine Omeros Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Catalyst Calendar

Proactively evaluate Omeros Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

18+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Omeros Corp’s relevant decision makers and contact details.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Sales & Consensus Forecasts

Understand the current and future drug revenue for Omeros Corp and assess market opportunity for new entrants with patient population 8-year forecasts.

50+

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Omidria: Irrigation Solution for eyes Omidria
Pipeline Narsoplimab
Narsoplimab- Renal diseases, COVID-19
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Regulatory Approval In July, the company announced OMS906 received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
2022 Regulatory Approval In January, the company submitted to the U.S. Food and Drug Administration (FDA) its response regarding the BLA for Narsoplimab in the treatment of HSCT-TMA.
2021 Asset Disposal In December, the company completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Omeros Corp Alexion Pharmaceuticals Inc Seagen Inc Harrow Health Inc Akari Therapeutics Plc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Seattle Boston Bothell Nashville New York
State/Province Washington Massachusetts Washington Tennessee New York
No. of Employees 213 3,837 2,675 182 9
Entity Type Public Private Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Gregory A. Demopulos, M.D. President; Chief Executive Officer; Chairman Executive Board 2013 63
Michael A. Jacobsen Treasurer; Chief Accounting Officer; Vice President - Finance Senior Management 2013 63
J. Steven Whitaker, M.D. Chief Medical Officer; Vice President - Clinical Development Senior Management 2019 66
George A. Gaitanaris, M.D., Ph.D. Vice President - Science; Chief Scientific Officer Senior Management 2012 65
Catherine A. Melfi, Ph.D. Chief Regulatory Officer; Vice President - Regulatory Affairs & Quality Systems Senior Management 2016 62
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?